Older people more likely to be infected through heterosexual sex and
to have more advanced disease when it is finally diagnosed, new study
reveals
Tuesday, October 24, 2017
Wednesday, October 4, 2017
6 IST
Treating blindness with gene therapy might be possible, says new study
Researchers at Oxford University are working towards a solution for blindness!
Blindness
RELATED STORIES
- Breast Cancer Awareness Month: A look at warning signs and know-how of the disease
- Biological sleep clock researchers bag Nobel Prize in Physiology or Medicine
- Speed climbing becomes one of the five sports to be included in the 2020 Tokyo Olympics programme
- Interesting facts on Ravana, the greatest mythological villain ever
- Gujarat will become the second state to introduce new EVMs with VVPAT
Blindness
is a condition where a person is totally sightless in both eyes. A
completely blind individual is unable to see anything at all. However,
the word is mostly used as a relative term to signify visual impairment
or low vision. A huge population suffers from vision impairment which
can range from mild to severe.
Researchers
at Oxford University are working towards a solution for blindness!
Their study has shown that gene therapy might help reverse blindness by
reprogramming cells to become more light sensitive. This will help cure
the most common cause of blindness in young people, which is Retinitis
Pigmentosa. In this condition, millions of light-sensitive photoreceptor
cells that line the retina are lost.
Currently, the study has been monitored for over a year in mice and was highly successful. They maintained vision during this time as they were able to recognise objects in their environment which indicated a high level of visual perception. The cells expressing melanopsin were able to respond to light and send visual signals to the brain.
Lead
author of the research Samantha de Silva, specialist registrar,
Ophthalmology and Clinical research training fellow at the University of
Oxford said, "There are many blind patients in our clinics and the
ability to give them some sight back with a relatively simple genetic
procedure is very exciting. Our next step will be to start a clinical
trial to assess this in patients."
Interested in General Knowledge and Current Affairs? Click here to stay informed and know what is happening around the world with our G.K. and Current Affairs section.
To get more updates on Current Affairs, send in your query by mail to education.intoday@gmail.com
ADVERTISING
Currently, the study has been monitored for over a year in mice and was highly successful. They maintained vision during this time as they were able to recognise objects in their environment which indicated a high level of visual perception. The cells expressing melanopsin were able to respond to light and send visual signals to the brain.
Facts on blindness:
- Over 350 million people are visually impaired due to various causes
- More than 50 million of these people are totally blind, unable to see light in either eye
- Eighty per cent of blindness cases occurs in people over 50 years old
- Common causes of blindness include diabetes, macular degeneration, traumatic injuries, infections of the cornea or retina and glaucoma
- Less common causes of blindness includes vitamin A deficiency, retinopathy of prematurity, vascular disease involving the retina or optic nerve including stroke, ocular inflammatory disease, retinitis pigmentosa, primary or secondary malignancies of the eye, congenital abnormalities, hereditary diseases of the eye, and chemical poisoning from toxic agents such as methanol
- Majority of the cases of blindness in the world is preventable through a combination of education, access to good medical care, and provision of glasses.
To get more updates on Current Affairs, send in your query by mail to education.intoday@gmail.com
Tuesday, September 26, 2017
HIV rates climbing among over-50s in UK and Europe, researchers warn
HIV rates are climbing in the over-50s in the UK and across Europe,
while the rate of new infections among younger people is dropping,
according to new research which warns that the epidemic may be taking a
new direction.
The study, from the European Centre for Disease Prevention and Control in Sweden, says that older people are most likely to be infected through heterosexual sex. They are also likely to have more advanced disease – which will be harder to treat and could be life-threatening – when it is finally picked up.
The study’s authors suggest that the over-50s may be either complacent or ignorant of the risks of HIV, which has dropped out of the headlines since it became a treatable disease. Their doctors also tend to assume that older people are not running risks through unsafe sex.
“Our findings suggest a new direction in which the HIV epidemic is evolving,” said lead author Dr Lara Tavoschi. “This potentially is a result of older peoples’ low awareness of HIV and how it is transmitted, leading to misconceptions and low perception of their own risk.
“This perception of older people not being at risk is shared by some healthcare providers, and HIV-related services focus more on younger people. Our study shows the need to ensure all ages are appropriately targeted by sexual health services.”
The study, published in the Lancet HIV journal, has found that one in six new cases of HIV are in people over the age of 50. Between 2004-2015, the rate of diagnosis in older people increased in 16 countries. That included the UK, where the rate of new diagnoses went up from 3.1 per 100,000 to 4.32. Belgium, Germany and Ireland also saw rises in the rate of infection among older people. By 2015, the rate in over-50s was highest in Estonia, Latvia, Malta, and Portugal.
While the rate of newly reported cases remained steady in those aged 15 to 49, it grew by 2.1% each year overall in older people across the 28 European nations, increasing from 2.1 people in every 100,000 in 2004 to 2.5 per 100,000 in 2015.
Infection through sex between men increased in both age groups between 2004-2015. Cases due to heterosexual sex reduced in younger people and remained stable in older people, while those attributable to injecting drug use also reduced in younger people but increased in older people.
The National Aids Trust said they had been aware of the rising rates in older people in the UK for some time and that action was needed to prevent these infections, such as targeting different age groups – not just the young – with information about their risks and offering HIV tests in places other than sexual health clinics, such as GP surgeries.
“In recent years there has been a steady increase in HIV diagnoses amongst people over the age of 50 in the UK, accounting for 9% of new diagnoses in 2006 and 17% in 2015,” said Kat Smithson, director of policy and campaigns. “The trend is not limited to, but is more prominent, in the heterosexual population. This presents a challenge to think about whether our prevention efforts meet the needs of changing demographics.”
Government cuts to public health budgets were damaging local authorities’ capacity to offer prevention and testing to older people,” she said. “High prevalence areas are spending a third less on HIV prevention than they were two years ago, and it’s targeted services that are suffering most. We are concerned that generalised health promotion around sexual health and HIV may not reach some smaller but growing areas of need, such as in the older heterosexual population. We have the tools to reverse this trend, but without investment we cannot use them.”
Professor Janet Seeley from the London School of Hygiene and Tropical Medicine, who wrote a commentary in the Lancet on the study, said that many older people did not think they were running a risk. “The main thing is complacency, and also they are in relationships where pregnancy is not a problem, so contraception isn’t something people consider,” she said. “I think there is very little publicity around HIV in Europe now that prevalence and incidence have gone down.”
The new infections were more often caused by heterosexual sex, she thought, because the gay community was far more aware of the risks. “Men of that particular age have gone through quite a lot themselves,” she said. It would be naive to expect governments to do anything about increasing awareness among the over-50s, given the pressures on health services, she acknowledged, but the study should encourage big campaigning groups – in particular the Terrence Higgins Trust, which had been working on the issue. “It is a very difficult group to reach,” she said. “It is very heterogeneous. If someone is going for a well-man or well-woman check up, it could be something the GP could mention.” It is difficult to ask people if they are having unprotected sex in a new relationship, but few people took notice of leaflets because they didn’t think they were relevant to them, she added.
Tavoschi
says that HIV services need to be geared up to the needs of this age
group. “Our findings illustrate a clear need to provide comprehensive
HIV prevention programmes, including education, access to condoms,
better testing opportunities, and treatment, targeted towards older
adults across Europe,” she said.
“We need to make both healthcare workers and the general population aware of this issue to reduce stigma and inform people about HIV risks and prevention methods. Testing in healthcare settings and innovative HIV test approaches – such as self-testing – need to be more easily accessible to older people to improve early diagnosis and fast-track treatment initiation. When achieved, this should help to prevent further transmission and lower the risk of severe health complications, which is of utmost importance among older adults living with HIV as their risk of mortality is higher as compared to younger individuals.”
The study, from the European Centre for Disease Prevention and Control in Sweden, says that older people are most likely to be infected through heterosexual sex. They are also likely to have more advanced disease – which will be harder to treat and could be life-threatening – when it is finally picked up.
The study’s authors suggest that the over-50s may be either complacent or ignorant of the risks of HIV, which has dropped out of the headlines since it became a treatable disease. Their doctors also tend to assume that older people are not running risks through unsafe sex.
“Our findings suggest a new direction in which the HIV epidemic is evolving,” said lead author Dr Lara Tavoschi. “This potentially is a result of older peoples’ low awareness of HIV and how it is transmitted, leading to misconceptions and low perception of their own risk.
“This perception of older people not being at risk is shared by some healthcare providers, and HIV-related services focus more on younger people. Our study shows the need to ensure all ages are appropriately targeted by sexual health services.”
The study, published in the Lancet HIV journal, has found that one in six new cases of HIV are in people over the age of 50. Between 2004-2015, the rate of diagnosis in older people increased in 16 countries. That included the UK, where the rate of new diagnoses went up from 3.1 per 100,000 to 4.32. Belgium, Germany and Ireland also saw rises in the rate of infection among older people. By 2015, the rate in over-50s was highest in Estonia, Latvia, Malta, and Portugal.
While the rate of newly reported cases remained steady in those aged 15 to 49, it grew by 2.1% each year overall in older people across the 28 European nations, increasing from 2.1 people in every 100,000 in 2004 to 2.5 per 100,000 in 2015.
Infection through sex between men increased in both age groups between 2004-2015. Cases due to heterosexual sex reduced in younger people and remained stable in older people, while those attributable to injecting drug use also reduced in younger people but increased in older people.
The National Aids Trust said they had been aware of the rising rates in older people in the UK for some time and that action was needed to prevent these infections, such as targeting different age groups – not just the young – with information about their risks and offering HIV tests in places other than sexual health clinics, such as GP surgeries.
“In recent years there has been a steady increase in HIV diagnoses amongst people over the age of 50 in the UK, accounting for 9% of new diagnoses in 2006 and 17% in 2015,” said Kat Smithson, director of policy and campaigns. “The trend is not limited to, but is more prominent, in the heterosexual population. This presents a challenge to think about whether our prevention efforts meet the needs of changing demographics.”
Government cuts to public health budgets were damaging local authorities’ capacity to offer prevention and testing to older people,” she said. “High prevalence areas are spending a third less on HIV prevention than they were two years ago, and it’s targeted services that are suffering most. We are concerned that generalised health promotion around sexual health and HIV may not reach some smaller but growing areas of need, such as in the older heterosexual population. We have the tools to reverse this trend, but without investment we cannot use them.”
Professor Janet Seeley from the London School of Hygiene and Tropical Medicine, who wrote a commentary in the Lancet on the study, said that many older people did not think they were running a risk. “The main thing is complacency, and also they are in relationships where pregnancy is not a problem, so contraception isn’t something people consider,” she said. “I think there is very little publicity around HIV in Europe now that prevalence and incidence have gone down.”
The new infections were more often caused by heterosexual sex, she thought, because the gay community was far more aware of the risks. “Men of that particular age have gone through quite a lot themselves,” she said. It would be naive to expect governments to do anything about increasing awareness among the over-50s, given the pressures on health services, she acknowledged, but the study should encourage big campaigning groups – in particular the Terrence Higgins Trust, which had been working on the issue. “It is a very difficult group to reach,” she said. “It is very heterogeneous. If someone is going for a well-man or well-woman check up, it could be something the GP could mention.” It is difficult to ask people if they are having unprotected sex in a new relationship, but few people took notice of leaflets because they didn’t think they were relevant to them, she added.
Advertisement
“We need to make both healthcare workers and the general population aware of this issue to reduce stigma and inform people about HIV risks and prevention methods. Testing in healthcare settings and innovative HIV test approaches – such as self-testing – need to be more easily accessible to older people to improve early diagnosis and fast-track treatment initiation. When achieved, this should help to prevent further transmission and lower the risk of severe health complications, which is of utmost importance among older adults living with HIV as their risk of mortality is higher as compared to younger individuals.”
New vaccine by Pune-based institute safe against severe rotavirus gastroenteritis: Study
To be launched in Nov; Centre orders 3.8 million doses for use in Universal Immunisation Programme
- Written by Anuradha Mascarenhas | Pune | Published:September 27, 2017 8:51 am
Related News
Rotavirus is the most common cause of diarrhoea and one of the leading causes of mortality among children who are under five years of age. Rotavirus accounts for approximately 40 per cent of all diarrhoea cases requiring treatment. A Rotavirus disease cannot be treated with antibiotics or other drugs.
The new vaccine, ROTASIL, is supposed to be orally administered to infants in a three-dose course at 6, 10, and 14 weeks of age, at the same time when the existing vaccinations under India’s Universal Immunisation Programme are administered.
The international non-profit PATH partnered with Serum Institute to evaluate this vaccine in the Phase 3 efficacy study. Initiated in May 2014, the study was conducted at clinical sites across six places in India — Pune, Kolkata, Sewagram, Delhi, Manipal, and Jammu. A total of 7,500 infants were followed from the time of vaccination until 2 years of age, to check the efficacy and safety outcomes.
“The Centre has placed an order for 3.8 million doses of the vaccine to use in the Universal Immunisation Programme, which serves 26 million children. The Serum Institute has manufactured the vaccine doses and will launch the vaccine in November,” Dr Rajeev Dhere, executive director of the Serum Institute of India, told The Indian Express.
It is estimated that 11.37 million episodes of rotavirus gastroenteritis occur every year in India alone, and they require 3.27 million outpatient visits and 872,000 in-patient admissions. In 2013, an estimated 47,100 rotavirus deaths occurred in India — 22 per cent of all rotavirus deaths that occurred globally. Currently, two rotavirus vaccines — Rotarix and RotaTeq — are licensed internationally and are prequalified by the World Health Organisation. A third vaccine, Rotavac, was recently licensed in India.
Despite the presence of these vaccines, there remains an overwhelming need for cost-effective and safe rotavirus vaccines for the worst-affected countries, said Dr Prasad Kulkarni, medical director at Serum Institute of India, who led the study.
Meanwhile, Médecins Sans Frontieres and Epicentre are also evaluating the efficacy and safety of ROTASIL in a separate Phase 3 study in Niger. That study is still ongoing, but results from the primary analysis also showed the vaccine to be highly efficient for the prevention of severe rotavirus diarrhoea, and with an excellent safety profile. The efficacy of the vaccine against severe and very severe rotavirus diarrhoea in the Niger study was 66.7 per cent and 78.8 per cent, respectively. These results were published in the New England Journal of Medicine in March 2017.
From Monday, pregnant women, new moms to get hot meals
By Express News Service |
Published: 27th September 2017 03:23 AM |
Last Updated: 27th September 2017 07:28 AM | A+A A- |
BENGALURU:
A maternal nutrition scheme, ‘Mathrupoorna’, which will provide one
freshly cooked meal to pregnant and lactating mothers, will be launched
on October 2. The scheme will replace the take-home meals that were
being offered as part of the supplementary nutrition programme under the
Integrated Child Development Scheme (ICDS).
A
pilot project was conducted in February at Manvi, H D Kote, Jamkhandi
and Madhugiri taluks, where 36,000 women were covered under the scheme.
The scheme is expected to benefit 12 lakh women in the state. Since the
meals will be cooked at anganwadis, the Department of Women and Child
Development (DWCD) has decided that meals served to children (3-6 years)
will also be the same so that meals do not have to cooked twice.
Keeping
in mind the restrictions placed on new mothers, meals will be allowed
to be taken home 30 days before delivery and 45 days after. In coastal
areas like Uttara Kannada and Udupi, where anganwadis are far away, DWCD
is considering allowing women to take the meals home.
Principal
Secretary to DWCD Uma Mahadevan said surveys held in the past decade
had shown that malnutrition, stunted growth and wasting has not reduced
much in children who do not have access to better facilities. “We
realised that to address the issue, it is not sufficient to focus on the
child alone, but also on the mother. Most of the women are anaemic and
calcium deficient before pregnancy and this contributes to poor health
of the child and in the long term, poorer prospects of leading a better
life,” she said.
While the DWCD will
focus on providing the meal, the Health and Family Welfare Department,
through ASHA workers and Auxiliary Nurse Midwives, will record their
development through mother and child tracking software, check
haemoglobin content and also counsel on birth preparedness.
Several issues to cover
The
successful implementation of the scheme which follows a life-cycle
approach, with focus on the mother and the child too stands a better
chance, depending on how DWCD manages several problems. There is some
resistance among anganwadi workers who feel they are not able to
concentrate on their core function as they are being frequently drawn
into other works like surveys and census. While stress is also being
laied on construction of toilets to prevent diarrhoea and other
infections, encouraging women and children to use the toilets when water
is a scarce commodity in north Karnataka is also a challenge. In
addition, the DWCD also has been unable to tackle child marriages
satisfactorily, despite conducting awareness campaigns. Also, younger
anaemic mothers have a higher rate of maternal mortality and also give
birth to underweight children. Whether families are willing to let these
young mothers have access to these meals is yet to be seen.
Wednesday, July 12, 2017
Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy
The therapy would involve genetically modifying a patient’s T cells to kill cancer and then infusing them back into the body. The dramatic effect of the treatment, known for years as CTL-019, was never questioned at the meeting. Of 68 young people receiving it, 52 of them had an excellent response almost immediately, with their cancer disappearing within the first three months. Three-quarters of those patients remained cancer-free six months after treatment.
Explaining their vote, many advisors were effusive. “It’s the most exciting thing I’ve seen in my lifetime,” said Timothy Cripe, a blood cancer and bone marrow transplant specialist at Nationwide Children’s Hospital in Columbus, OH.
Others had high praise for the drug’s marketer, Novartis (NYSE: NVS), and its plans to keep a close eye on the potentially severe side effects of CAR-T if it becomes a commercial product. Those so-called “risk mitigation” plans were one of the main concerns that the FDA, in documents released Monday, asked its advisors to consider.
The main side effect of CTL-019 is cytokine release syndrome, a blistering immune reaction to the drug and the detritus of dying cancer cells. It can be deadly, with spiking fevers and other symptoms, if medical staff aren’t properly trained for it. Novartis said it would train staffers at 30 to 35 medical centers and take other measures, as well.
At the FDA’s behest, the advisory panel spent much of the day discussing long-term side effects, too—the possibility that the T cell modification could go awry, and years down the road cause secondary cancers. It’s a concern that stems from the early days of gene therapy, when the genetic tweaking of patient’s cells with a modified virus turned on cancer-causing genes.
Novartis officials said they would follow patients for at least 15 years and investigate any cases of secondary cancers. Committee member Catherine Bollard, who runs an immunotherapy center at the Children’s Research Institute in Washington, DC, said she would like Novartis also to investigate when patients relapse with altered forms of leukemia.
The committee members said it was hard to assess the long-term risk, but in patients with no other treatment options, the near-term benefits of CAR-T therapy more than tipped the scales. “You have to be a long-term survivor to experience [long-term] toxicity,” said Bruce Roth of the Washington University School of Medicine in St. Louis, MO. CTL-019 should give kids with ALL a chance for long-term survival, he said.
In a field that has plenty of pressing questions about severe, even deadly short-term side effects— including brain swelling that was seen in trials of CAR-T therapies run by competing companies —many observers were left wondering why the FDA highlighted the long-term risks of the CAR-T causing another cancer, perhaps years into the future. One possibility is that the agency is anticipating that CAR-T products will be developed for patients who aren’t at the end of the line. For example, the engineered T cells could be used as an “adjuvant” or additional therapy after a previous treatment has wiped out all but the last traces of cancer, said Richard Maziarz, a blood cancer specialist at Oregon Health and Science University in Portland.
“In those settings, the downstream effect [of triggering a secondary cancer] is conceivable,” said Maziarz. (Maziarz was not part of today’s advisory committee. He has treated adult patients with CTL-019 as part of a different Novartis study.)
The news today buoyed Novartis stock, which was up $1.22, or nearly 1.5 percent. Based in Switzerland, but with much of its R&D in the U.S., Novartis was the first biopharma group to dive into the CAR-T field in a big way when in 2012 it launched a collaboration with the University of Pennsylvania. Much of the early work on CTL-019, now renamed tisagenlecleucel, took place in the university’s labs and clinics.
Novartis disbanded its cell and gene therapy group last year but vowed to press on with CTL-019. Approval in pediatric ALL now seems all but assured; the FDA rarely bucks the advice of its advisory committees. Novartis is also vying to have CTL-019 approved to treat adults with the most common forms of non-Hodgkin lymphoma. Beyond that, the company’s plans with CAR-T are unclear. Penn has a next-generation CAR-T under development, dubbed CTL-119, which is not licensed to Novartis.
Novartis also convinced the advisory committee that its complicated manufacturing process could be fast and consistent. There are many links in the production chain, which requires extracting T cells from a patient, shipping them to a lab for genetic modification, making viral vectors that insert new DNA into the T cells, then shipping the cells back to be dripped through an IV back into the patient.
Such a complex system for making personalized treatments is likely to drive up their cost, and the next big hurdle (assuming an FDA approval this fall) is to win over insurers. The complexity can also introduce other kinds of risk, such as failure of the cells to repopulate the patients’ immune system. “I think it will be important in the commercial phase to assess both failure rates and turnaround times for CAR-T production,” said Krishna Komanduri, director of the Sylvester Comprehensive Cancer Center Adult Stem Cell Transplant Program at the University of Miami, who has treated patients with other experimental CAR-Ts, but not the one from Novartis. “Either delays or failure of production will have clinical consequences for the highest risk patients.”
Subscribe to:
Posts (Atom)